ArticleJournal of food science2026
Hericium erinaceus β-Glucan Improves Post-Prandial Glycemic Homeostasis in Association With Changes in Akkermansia muciniphila, Serum Metabolites, and Gut Hormones.
Article in Journal of food science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Post-prandial glycemia is an important indicator of metabolic health and early glucose dysregulation. Mushroom-derived β-glucans have potential as functional ingredients for glycemic control, but their comparative efficacy and regulatory mechanisms remain unclear. In this study, β-glucans from oyster mushroom (OMBG), Ganoderma lucidum (GBG), and Hericium erinaceus (HEBG) were evaluated using structural characterization, functional assays, simulated digestion, colonic fermentation, and in vivo experiments, with oat β-glucan (OBG) included as a reference. OBG showed strong glucose diffusion-retarding and enzyme-inhibitory activities in vitro, whereas HEBG exhibited the best overall performance among mushroom-derived β-glucans, particularly in glucose adsorption, glucose diffusion retardation, and α-glucosidase inhibition. During simulated gastrointestinal digestion, HEBG reduced starch hydrolysis and glucose release, and during colonic fermentation it supported microbial growth and carbohydrate utilization. In mice, HEBG improved oral glucose tolerance without affecting body weight, food intake, or organ indices. HEBG treatment was associated with reduced intestinal Sglt-1 expression, enhanced barrier-related markers, including tight junction proteins and Muc2, and increased GLP-1 and PYY secretion. Multi-omics analyses further indicated that HEBG altered gut microbiota composition, particularly enriching Akkermansia muciniphila, and was associated with changes in serum metabolites related to carbohydrate and lipid metabolism. These findings suggest that HEBG may improve post-prandial glucose homeostasis in association with a gut microbiota-metabolite-gut hormone network. PRACTICAL APPLICATIONS: HEBG may serve as a mushroom-derived functional ingredient for post-prandial glycemic management and could be incorporated into supplements, beverages, or starch-based foods to help delay starch digestion and glucose release. Further studies should assess its processing stability and functional retention during food manufacturing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.